Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:MLTXNASDAQ:PTCTNASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$34.86-3.4%$31.92$23.42▼$62.58$2.03B0.73651,408 shs85,061 shsMLTXMoonLake Immunotherapeutics$48.00-1.8%$42.55$31.42▼$58.26$3.06B1.27383,991 shs101,589 shsPTCTPTC Therapeutics$48.19-1.8%$48.21$29.02▼$58.38$3.83B0.5860,742 shs96,383 shsRAPPRapport Therapeutics$12.17+1.1%$11.01$6.43▼$29.74$444.21MN/A163,835 shs16,694 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+7.72%+5.02%+39.21%-15.46%MLTXMoonLake Immunotherapeutics0.00%-2.43%-1.10%+33.31%+10.31%PTCTPTC Therapeutics0.00%-2.14%-6.44%+13.90%+57.68%RAPPRapport Therapeutics0.00%+5.34%-4.90%+26.60%-49.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0093 of 5 stars3.41.00.04.31.40.81.9MLTXMoonLake Immunotherapeutics1.9892 of 5 stars3.51.00.00.02.22.50.0PTCTPTC Therapeutics4.3094 of 5 stars4.31.00.04.41.50.81.3RAPPRapport Therapeutics1.3124 of 5 stars3.50.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6062.53% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$74.5060.68% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0033.28% UpsideRAPPRapport Therapeutics 3.00Buy$28.00132.56% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, MLTX, PTCT, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M57.21N/AN/A$27.02 per share1.33MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/APTCTPTC Therapeutics$806.78M4.79N/AN/A($14.24) per share-3.42RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.21N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.49N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)Latest RAPP, MLTX, PTCT, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93MLTXMoonLake Immunotherapeutics0.1821.1121.11PTCTPTC TherapeuticsN/A3.893.85RAPPRapport TherapeuticsN/A31.0131.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%PTCTPTC TherapeuticsN/ARAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%MLTXMoonLake Immunotherapeutics12.05%PTCTPTC Therapeutics5.50%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.06 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.30 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARAPP, MLTX, PTCT, and AGIO HeadlinesRecent News About These CompaniesRapport Therapeutics stock rating reiterated as Buy by TD CowenJuly 2, 2025 | uk.investing.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)...June 12, 2025 | marketbeat.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comRapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 16, 2025 | finance.yahoo.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comInductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI PlatformMay 7, 2025 | finance.yahoo.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%May 3, 2025 | aaii.comAMise à disposition du rapport financier annuel 2024April 30, 2025 | globenewswire.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%April 29, 2025 | aaii.comARapport Therapeutics to Participate in Upcoming Investor ConferencesApril 22, 2025 | globenewswire.comMeloni and Trump: An Oval Office Meeting With Rapport and BanterApril 18, 2025 | nytimes.comRapport Therapeutics initiated with an Outperform at Citizens JMPApril 9, 2025 | markets.businessinsider.comBuy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS DisordersApril 9, 2025 | tipranks.comJMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform RecommendationApril 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPP, MLTX, PTCT, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$34.86 -1.21 (-3.35%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$48.00 -0.89 (-1.82%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.PTC Therapeutics NASDAQ:PTCT$48.19 -0.88 (-1.79%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rapport Therapeutics NASDAQ:RAPP$12.17 +0.13 (+1.08%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
